JP2010500357A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500357A5
JP2010500357A5 JP2009523836A JP2009523836A JP2010500357A5 JP 2010500357 A5 JP2010500357 A5 JP 2010500357A5 JP 2009523836 A JP2009523836 A JP 2009523836A JP 2009523836 A JP2009523836 A JP 2009523836A JP 2010500357 A5 JP2010500357 A5 JP 2010500357A5
Authority
JP
Japan
Prior art keywords
interfering rna
small interfering
strand
medical system
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009523836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500357A (ja
Filing date
Publication date
Priority claimed from US11/501,147 external-priority patent/US7732591B2/en
Application filed filed Critical
Publication of JP2010500357A publication Critical patent/JP2010500357A/ja
Publication of JP2010500357A5 publication Critical patent/JP2010500357A5/ja
Pending legal-status Critical Current

Links

JP2009523836A 2006-08-08 2007-08-08 頭蓋内のｓｉＲＮＡの運搬を通じたハンチントンの疾患治療用の組成物、デバイス及び方法 Pending JP2010500357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/501,147 US7732591B2 (en) 2003-11-25 2006-08-08 Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
PCT/US2007/017659 WO2008021149A2 (en) 2006-08-08 2007-08-08 Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna

Publications (2)

Publication Number Publication Date
JP2010500357A JP2010500357A (ja) 2010-01-07
JP2010500357A5 true JP2010500357A5 (https=) 2010-10-07

Family

ID=39082586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523836A Pending JP2010500357A (ja) 2006-08-08 2007-08-08 頭蓋内のｓｉＲＮＡの運搬を通じたハンチントンの疾患治療用の組成物、デバイス及び方法

Country Status (6)

Country Link
US (1) US7732591B2 (https=)
EP (1) EP2056840B1 (https=)
JP (1) JP2010500357A (https=)
CN (1) CN101522202B (https=)
CA (1) CA2660153C (https=)
WO (1) WO2008021149A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994149B2 (en) * 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8173614B2 (en) * 2007-01-03 2012-05-08 Medtronic, Inc. Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
US8957038B2 (en) 2009-07-15 2015-02-17 Medtronic, Inc. Treatment of neurological disorders
CA2941650A1 (en) * 2014-03-05 2015-09-11 Humanetics Corporation Predicting and reducing cognitive decline based on gsk-3 levels
US10786674B2 (en) 2016-03-08 2020-09-29 Medtronic, Inc. Medical therapy target definition
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
WO2019161034A1 (en) * 2018-02-14 2019-08-22 Neuroelectrics Corporation Systems and methods for treating brain disease using targeted neurostimulation
EP4663758A3 (en) * 2018-05-09 2026-04-29 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
EP4051795A1 (en) * 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
CN113846122B (zh) * 2021-08-16 2023-08-25 中国医学科学院医学生物学研究所 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB2181691B (en) 1985-10-21 1990-05-23 Porvair Ltd Gloves
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2109955A1 (en) 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
US5236908A (en) 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
US5354326A (en) 1993-01-27 1994-10-11 Medtronic, Inc. Screening cable connector for interface to implanted lead
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
CA2179014C (en) 1993-12-17 2003-07-29 Spinal Cord Society Method for inducing dna synthesis in neurons
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5534350A (en) 1994-12-28 1996-07-09 Liou; Derlin Powerfree glove and its making method
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5942455A (en) 1995-11-14 1999-08-24 Drexel University Synthesis of 312 phases and composites thereof
JPH09268067A (ja) 1996-03-29 1997-10-14 Asahi Glass Co Ltd 炭化ケイ素部材の製造方法
WO2000062828A1 (en) 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US7189222B2 (en) 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
WO1998012311A2 (en) 1996-09-11 1998-03-26 The General Hospital Corporation Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US5882561A (en) 1996-11-22 1999-03-16 Drexel University Process for making a dense ceramic workpiece
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US5968059A (en) 1997-03-06 1999-10-19 Scimed Life Systems, Inc. Transmyocardial revascularization catheter and method
GB9706463D0 (en) 1997-03-27 1997-05-14 Medical Res Council A model of inflamation in the central nervous system for use in the study of disease
NZ333334A (en) 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
US5931861A (en) 1997-04-25 1999-08-03 Medtronic, Inc. Medical lead adaptor having rotatable locking clip mechanism
US5782892A (en) 1997-04-25 1998-07-21 Medtronic, Inc. Medical lead adaptor for external medical device
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6231969B1 (en) 1997-08-11 2001-05-15 Drexel University Corrosion, oxidation and/or wear-resistant coatings
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6151525A (en) 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2000065042A1 (en) 1999-04-28 2000-11-02 The Board Of Trustees Of The Leland Stanford Junior University P element derived vector and methods for its use
GB9928248D0 (en) 1999-12-01 2000-01-26 Gill Steven S An implantable guide tube for neurosurgery
US6310048B1 (en) 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
US6461989B1 (en) 1999-12-22 2002-10-08 Drexel University Process for forming 312 phase materials and process for sintering the same
US20030092003A1 (en) 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
AU2625501A (en) 1999-12-30 2001-07-16 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6945969B1 (en) 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US6551290B1 (en) 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
US20050209179A1 (en) 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
AU2001288317A1 (en) 2000-08-30 2002-03-13 Agion Technologies, Llc Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties
US6659995B1 (en) 2000-11-17 2003-12-09 Syde A. Taheri Autologous myocyte micro granual retrieval and implantation (AMMGRI)
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
CA2450809A1 (en) 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
WO2003013437A2 (en) 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US6944497B2 (en) 2001-10-31 2005-09-13 Medtronic, Inc. System and method of treating stuttering by neuromodulation
US20030105047A1 (en) 2001-11-30 2003-06-05 Medtronic, Inc. Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors
US20030120282A1 (en) 2001-12-24 2003-06-26 Scouten Charles W. Stereotaxic manipulator with retrofitted linear scales and digital display device
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US7270653B2 (en) 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
US20040023855A1 (en) 2002-04-08 2004-02-05 John Constance M. Biologic modulations with nanoparticles
US20040018520A1 (en) 2002-04-22 2004-01-29 James Thompson Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
AU2003237686A1 (en) 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
JP3968365B2 (ja) 2002-07-25 2007-08-29 日世株式会社 ロールコーン製造装置
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20050048641A1 (en) 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US8512290B2 (en) 2003-03-20 2013-08-20 Boston Scientific Scimed, Inc. Devices and methods for delivering therapeutic or diagnostic agents
US20040186528A1 (en) 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
EP1620133B1 (en) 2003-05-01 2015-12-09 Genzyme Corporation Gene therapy for neurometabolic disorders
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US7917228B2 (en) 2003-05-13 2011-03-29 Medtronic, Inc. Medical lead adaptor assembly
US20060014165A1 (en) 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
DK2821085T3 (da) 2003-09-12 2020-08-03 Univ Massachusetts Rna-interferens til behandling af "gain-of-function"-forstyrrelser
WO2005065242A2 (en) 2003-12-29 2005-07-21 Am Biosolutions Method of treating cancer using platelet releasate
US20050153353A1 (en) 2004-01-09 2005-07-14 Bernd Meibohm Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
WO2006022639A1 (en) 2004-07-21 2006-03-02 Applera Corporation Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2006047250A2 (en) 2004-10-22 2006-05-04 Neurologix, Inc. Use of apoptosis inhibiting compounds in degenerative neurological disorders
NL1028134C2 (nl) 2005-01-27 2006-07-31 Sara Lee De Nv Werkwijze voor het bereiden van een voor consumptie geschikte drank uit ten minste twee op te lossen en/of te extraheren ingredienten en een hoeveelheid vloeistof.
TW200635542A (en) 2005-04-01 2006-10-16 Dharma Drum Mountain Method of establishing and using commemorative material
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US20080280843A1 (en) 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
GB0520235D0 (en) 2005-10-05 2005-11-16 Astrazeneca Ab Method
JP5111385B2 (ja) 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン遺伝子の発現を抑制するための組成物および方法
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN200970210Y (zh) 2006-10-12 2007-11-07 王会才 拖把清洗脱水机

Similar Documents

Publication Publication Date Title
JP2010500357A5 (https=)
Douglas et al. Splicing therapy for neuromuscular disease
JP2018520646A5 (https=)
CA2660153A1 (en) Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
JP2008514223A5 (https=)
JP2005506087A5 (https=)
US7994149B2 (en) Method for treatment of Huntington's disease through intracranial delivery of sirna
Kenney et al. Recombinant MG53 protein protects mice from lethal influenza virus infection
Schmitz et al. Chronic hyperosmotic stress inhibits renal Toll-Like Receptors expression in striped catfish (Pangasianodon hypophthalmus, Sauvage) exposed or not to bacterial infection
US20230193278A1 (en) MULTI-TARGETED siRNA FOR TREATING CANCERS
WO2019033051A1 (en) RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR)
CN116459265A (zh) 预防或治疗鼻病毒感染的药物
JP2013504603A5 (https=)
Apostolopoulos et al. Smart therapies against global pandemics: A potential of short peptides
US20240352466A1 (en) APTAMER-siRNA FUSIONS
KR101607629B1 (ko) miRNA를 이용한 C형 간염 바이러스 감염 질환의 예방 또는 치료
Heo et al. The first case of non-retrospective clinical identification of severe fever with thrombocytopenia syndrome patient in 2013 in South Korea
CN110337494B (zh) 表达靶向CDK9的RNAi效应子的H-1 PV
CN104940955B (zh) 一种microRNA在制备治疗流感的药物中的应用
JP2018520150A (ja) 嚢胞性線維症の処置のための方法及び医薬組成物
Rethnam et al. Differential expression of neuropeptide Y Y1 receptors during pulpal inflammation
SA517390457B1 (ar) تكوين فيروسي صغير
US20220396794A1 (en) APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
Wang et al. Characterization and expression analysis of key genes of pathogen-associated molecular pattern-triggered Toll-like receptor 5 signaling in the lined seahorse responses to bacterial and parasitic infection
Li et al. Cherry Valley Duck Galectin-2 Plays an Essential Role in Avian Pathogenic Escherichia coli Infection-Induced Innate Immune Response